although improvement in longterm health is no longer an indication for menopausal hormone therapy evidence supporting fewer adverse events in younger women combined with its high overall effectiveness has reinforced its usefulness for shortterm treatment of menopausal symptomsmenopausal therapy has been provided not only by commercially available products but also by compounding or creation of an individualized preparation in response to a health care providers prescription to create a medication tailored to the specialized needs of an individual patientthe womens health initiative findings coupled with an increase in the directtoconsumer marketing and media promotion of compounded bioidentical hormonal preparations as safe and effective alternatives to conventional menopausal hormone therapy have led to a recent increase in the popularity of compounded bioidentical hormones as well as an increase in questions about the use of these preparationsnot only is evidence lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal hormone therapy but these claims also pose the additional risks of variable purity and potency and lack efficacy and safety datathe committee on gynecologic practice of the american college of obstetricians and gynecologists and the practice committee of the american society for reproductive medicine provide an overview of the major issues of concern surrounding compounded bioidentical menopausal hormone therapy and provide recommendations for patient counselingcopyright  2012 american society for reproductive medicinepublished by elsevier inc all rights reserved